These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15837702)

  • 1. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.
    Comella P; Massidda B; Filippelli G; Palmeri S; Natale D; Farris A; De Vita F; Buzzi F; Tafuto S; Maiorino L; Mancarella S; Leo S; Lorusso V; De Lucia L; Roselli M
    Ann Oncol; 2005 Jun; 16(6):878-86. PubMed ID: 15837702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
    Comella P; Crucitta E; De Vita F; De Lucia L; Farris A; Del Gaizo F; Palmeri S; Lannelli A; Mancarella S; Tafuto S; Maiorino L; Buzzi F; De Cataldis G;
    Ann Oncol; 2002 Jun; 13(6):866-73. PubMed ID: 12123331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
    Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
    Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
    Comella P; Massidda B; Filippelli G; Farris A; Natale D; Barberis G; Maiorino L; Palmeri S; Cannone M; Condemi G;
    J Cancer Res Clin Oncol; 2009 Feb; 135(2):217-26. PubMed ID: 18719941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
    Kalofonos HP; Aravantinos G; Kosmidis P; Papakostas P; Economopoulos T; Dimopoulos M; Skarlos D; Bamias A; Pectasides D; Chalkidou S; Karina M; Koutras A; Samantas E; Bacoyiannis C; Samelis GF; Basdanis G; Kalfarentzos F; Fountzilas G
    Ann Oncol; 2005 Jun; 16(6):869-77. PubMed ID: 15855226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
    Comella P; De Vita F; Mancarella S; De Lucia L; Biglietto M; Casaretti R; Farris A; Ianniello GP; Lorusso V; Avallone A; Cartenì G; Leo SS; Catalano G; De Lena M; Comella G
    Ann Oncol; 2000 Oct; 11(10):1323-33. PubMed ID: 11106123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
    Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G
    Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
    Janinis J; Papakostas P; Samelis G; Skarlos D; Papagianopoulos P; Fountzilas G
    Ann Oncol; 2000 Feb; 11(2):163-7. PubMed ID: 10761750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
    Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
    Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.
    Zori Comba A; Blajman C; Richardet E; Bella S; Vilanova M; Cóppola F; Van Kooten M; Rodger J; Giglio R; Balbiani L; Perazzo F; Montiel M; Chacón M; Pujol F; Mickiewicz E; Cazap E; Recondo G; Lastiri F; Simon J; Wasserman E; Schmilovich A
    Eur J Cancer; 2001 May; 37(8):1006-13. PubMed ID: 11334726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.
    Mosconi S; Cascinu S; Zaniboni A; Catalano V; Giordani P; Beretta GD; Martignoni G; Pancera G; Baldelli AM; Poletti P; Curti C; Labianca R
    Tumori; 2000; 86(6):465-9. PubMed ID: 11218187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Tournigand C; André T; Achille E; Lledo G; Flesh M; Mery-Mignard D; Quinaux E; Couteau C; Buyse M; Ganem G; Landi B; Colin P; Louvet C; de Gramont A
    J Clin Oncol; 2004 Jan; 22(2):229-37. PubMed ID: 14657227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
    Comella P; Massidda B; Natale D; Putzu C; Sandomenico C; Filippelli G; Palmeri S; Condemi G; Vessia G; Barberis G; Ionta MT; Tafuto S; Barbato E
    Clin Colorectal Cancer; 2011 Mar; 10(1):42-7. PubMed ID: 21609935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.
    Hospers GA; Schaapveld M; Nortier JW; Wils J; van Bochove A; de Jong RS; Creemers GJ; Erjavec Z; de Gooyer DJ; Slee PH; Gerrits CJ; Smit JM; Mulder NH
    Ann Oncol; 2006 Mar; 17(3):443-9. PubMed ID: 16500914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.